GSK Glaxosmithkline

GlaxoSmithKline Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the following segments: Pharmaceuticals, Vaccines, Consumer Healthcare, and Corporate Executive Team (CET). The Pharmaceuticals segment focuses on developing medicines in respiratory and infectious diseases, oncology, and immuno-inflammation. The Vaccines segment produces pediatric and adult vaccines to prevent a range of infectious diseases including, hepatitis A and B, diphtheria, tetanus and whooping cough, measles, mumps and rubella, polio, typhoid, influenza, and bacterial meningitis. The Consumer Healthcare segment develops and markets brands in the oral health, pain relief, respiratory, nutrition and gastro intestinal, and skin health categories. The CET segment refers to the management of business activities. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.
Company profile
Ticker
GSK
Exchange
Website
CEO
Emma Walmsley
Employees
Incorporated
Location
Industry (SIC)
SEC CIK
Corporate docs
GSK stock data
()
News
Benzinga's Bulls And Bears Of The Week: Alphabet, Coinbase, GE, Quantumscape, Tesla And More
17 Apr 21
BofA Says GlaxoSmithKline's Decision To Halt Feladilimab Studies Is Disappointing
15 Apr 21
Analyzing The Price Action In GlaxoSmithKline Stock Today
15 Apr 21
GSK, Vir Biotechnology Announce European Medicines Agency Review Of Dual-Action Monoclonal Antibody VIR-7831 For Early Treatment of COVID-19
15 Apr 21
Benzinga Pro's Top 5 Stocks To Watch For Thursday, Apr. 15, 2021: DELL, AEO, GSK, UNH, INO
15 Apr 21
Press releases
GSK and Vir Biotechnology Announce EMA Review of Dual-Action Monoclonal Antibody VIR-7831 for the Early Treatment of COVID-19
15 Apr 21
GSK Global Head of Vaccine Research and Development Joins Viome To Tackle Chronic Diseases
15 Apr 21
Thinking about buying stock in Dell Technologies, American Eagle Outfitters, Wrap Technologies, PPD Inc, or GlaxoSmithKline?
15 Apr 21
BioSig Invited to Join Alliance for Artificial Intelligence in Healthcare (AAIH)
9 Apr 21
Flonase teams up with Major League Baseball and World Series champion Cody Bellinger to change the game on allergy season
1 Apr 21
Calendar
12 Mar 21
18 Apr 21
Financial summary
Quarter (USD) |
Dec 20 | Dec 19 | Dec 18 | Dec 17 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) |
Dec 20 | Dec 19 | Dec 18 | Dec 17 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Financial data from company earnings reports.
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
17 Feb 21 | Glaxosmithkline | Common Stock | Buy | Aquire P | Yes | No | 18 | 150,000 | 2.7M | 1,183,663 |
17 Feb 21 | Glaxosmithkline | Common Stock | Conversion | Aquire C | Yes | No | 0 | 327,852 | 0 | 1,033,663 |
17 Feb 21 | Glaxosmithkline | Common Stock | Conversion | Aquire C | Yes | No | 0 | 247,324 | 0 | 705,811 |
17 Feb 21 | Glaxosmithkline | Common Stock | Conversion | Aquire C | Yes | No | 0 | 458,487 | 0 | 458,487 |
17 Feb 21 | Glaxosmithkline | Series D Preferred Stock Common Stock | Conversion | Dispose C | Yes | No | 0 | 1,737,619 | 0 | 0 |
17 Feb 21 | Glaxosmithkline | Series C Preferred Stock Common Stock | Conversion | Dispose C | Yes | No | 0 | 3,125,000 | 0 | 0 |
17 Feb 21 | Glaxosmithkline | Series A Preferred Stock Common Stock | Conversion | Dispose C | Yes | No | 0 | 7,119,850 | 0 | 0 |
24 Jul 20 | Glaxosmithkline | Common Stock | Buy | Aquire P | Yes | No | 2.25 | 1,260,504 | 2.84M | 4,626,389 |
24 Jul 20 | Glaxosmithkline | Warrant Common Stock | Buy | Aquire P | Yes | No | 0.125 | 1,260,504 | 157.56K | 1,260,504 |
21 Jul 20 | Glaxosmithkline | Common Stock | Buy | Aquire P | Yes | No | 18 | 361,111 | 6.5M | 2,248,304 |
Institutional ownership Q4 2020
Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.
12.0% owned by funds/institutions
13F holders |
Current |
---|---|
Total holders | 784 |
Opened positions | 112 |
Closed positions | 124 |
Increased positions | 234 |
Reduced positions | 327 |
13F shares |
Current |
---|---|
Total value | 11.08B |
Total shares | 301.11M |
Total puts | 2.68M |
Total calls | 2.03M |
Total put/call ratio | 1.3 |
Largest owners |
Shares | Value |
---|---|---|
Dodge & Cox | 62.94M | $2.32B |
FMR | 19.36M | $712.49M |
Capital International Investors | 17.62M | $648.41M |
TROW T. Rowe Price | 16.55M | $608.9M |
Fisher Asset Management | 16.53M | $608.18M |
RY Royal Bank Of Canada | 14.71M | $541.39M |
Renaissance Technologies | 14.27M | $525.19M |
Hotchkis & Wiley Capital Management | 10.36M | $381.37M |
STT State Street | 9.51M | $354.62M |
Black Creek Investment Management | 7.44M | $273.91M |
Financial report summary
?Competition
Heron Therapeutics • Geovax Labs • Immunogen • Delcath Systems • Adamis Pharmaceuticals • Titan Pharmaceuticals, Inc. • FibroGen • Guided Therapeutics • Mymetics • AIM ImmunoTechContent analysis
?
Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. sophomore Avg
|
New words:
adherence, adolescent, adult, Advil, Agency, agile, albuterol, analyze, Annex, antibiotic, attack, attractive, augment, automated, automation, Avolve, ban, Bancroft, behavior, beneficial, Benlysta, Bexsero, Blenrep, bond, Boostrix, carefully, chronic, classic, climate, Cloud, complement, Contac, court, Crispr, CureVac, daprodustat, deployment, Digestive, diligence, disagree, disease, disguised, Dovato, drew, Duvroq, dynamic, EC, EHS, elongated, embracing, empower, Encepur, energy, erode, extremely, feedback, feladilimab, final, Flonase, Flovent, fourth, hacking, harmonization, hospital, IBA, importantly, imposition, indefinite, inequality, Infanrix, inhibitor, intensive, interconnected, interconnectivity, Intercontinental, Juluca, Justice, kidney, learning, legitimacy, lifted, linkage, loan, machine, macroeconomic, medium, Menveo, modern, month, myeloma, nasal, nitrosamine, Nucala, occasionally, OECD, optimize, otilimab, Otrivin, outperform, paediatric, Panadol, panel, PARP, partially, Pediarix, pharmacovigilance, posed, premium, presence, presumption, prioritization, prioritized, pronounced, protectionism, quickly, Rabipur, ransomware, recoverable, refractory, regimen, relapsed, Relenza, repercussion, resilience, rest, resurgence, rooted, Scop, seize, Sensodyne, social, solicit, sophisticated, sought, Specialty, standalone, Sterile, streamline, strength, summarize, summarized, synergy, temporarily, Theraflu, timeline, Tivicay, traditional, Transderm, Trelegy, tuition, turn, twelve, undermine, understood, unfavorable, unique, unknown, unregulated, urgent, variable, Ventolin, vir, water, weak, week, worsened, Zejula
Removed:
aid, analyse, andBoostrix, andTivicay, asserted, background, Beecham, commercialisation, Cooperation, coverage, cybersecurity, defendant, determination, Ebola, Ellipta, erosion, evident, frequently, GDPR, geographical, Glaxo, inappropriate, incremental, inherently, inInternal, Insufficient, integral, intent, interaction, labelling, measurable, media, merged, method, misuse, newer, November, ofBenlysta, ofSeretide, older, outbreak, outsourced, phasing, predecessor, preventing, procured, publishing, punitive, pursuit, remeasurement, replacing, side, SmithKline, solution, spread, storm, summarise, sustainability, therapeutic, Theravance, unanticipated, unauthorised, unpredictable, Wellcome, widely
Financial reports
20-F
2020 FY
Annual report (foreign)
12 Mar 21
20-F
2019 FY
Annual report (foreign)
6 Mar 20
20-F
2018 FY
Annual report (foreign)
15 Mar 19
20-F/A
2017 FY
Annual report (foreign) (amended)
19 Mar 18
20-F
2017 FY
Annual report (foreign)
15 Mar 18
20-F
2016 FY
Annual report (foreign)
16 Mar 17
20-F
2015 FY
Annual report (foreign)
17 Mar 16
20-F
2014 FY
Annual report (foreign)
26 Feb 15
20-F
2013 FY
Annual report (foreign)
27 Feb 14
20-F
2012 FY
Annual report (foreign)
7 Mar 13
Current reports
6-K
Director/pdmr Shareholding
16 Apr 21
6-K
Director/pdmr Shareholding
15 Apr 21
6-K
Director/pdmr Shareholding
15 Apr 21
6-K
Director/pdmr Shareholding
14 Apr 21
6-K
Director/pdmr Shareholding
14 Apr 21
6-K
Director/pdmr Shareholding
12 Apr 21
6-K
Director/pdmr Shareholding
12 Apr 21
6-K
Director/pdmr Shareholding
9 Apr 21
6-K
Director/pdmr Shareholding
9 Apr 21
6-K
Directorate Change
6 Apr 21
Registration and prospectus
F-3ASR
Automatic shelf registration (foreign)
26 Mar 21
F-6 POS
Automatic registration for ADRs (post-effective amendment, foreign)
15 Mar 21
25-NSE
Exchange delisting
13 Oct 20
8-A12B
Registration of securities on exchange
1 Oct 20
424B2
Prospectus for primary offering
30 Sep 20
FWP
Free writing prospectus
28 Sep 20
FWP
Free writing prospectus
28 Sep 20
424B2
Prospectus for primary offering
28 Sep 20
S-8
Registration of securities for employees
20 Dec 19
F-6
Registration for ADRs (foreign)
19 Jul 19
Proxies
No filings
Other
IRAN
Disclosure regarding Iran Threat Reduction and Syria Human Rights Act
12 Mar 21
SD
Conflict minerals disclosure
29 May 20
IRAN
Disclosure regarding Iran Threat Reduction and Syria Human Rights Act
6 Mar 20
EFFECT
Notice of effectiveness
30 Jul 19
SD
Conflict minerals disclosure
31 May 19
CT ORDER
Confidential treatment order
2 May 19
IRAN
Disclosure regarding Iran Threat Reduction and Syria Human Rights Act
15 Mar 19
SD
Conflict minerals disclosure
30 May 18
IRAN
Disclosure regarding Iran Threat Reduction and Syria Human Rights Act
15 Mar 18
SD
Conflict minerals disclosure
30 May 17
Ownership
SC 13D/A
BICYCLE THERAPEUTICS / GLAXOSMITHKLINE ownership change
16 Apr 21
SC 13D/A
Pandion Therapeutics / GLAXOSMITHKLINE ownership change
8 Apr 21
4
Change in insider ownership
19 Feb 21
SC 13G/A
GENOCEA BIOSCIENCES / GLAXOSMITHKLINE ownership change
12 Feb 21
SC 13G/A
Progyny / GLAXOSMITHKLINE ownership change
12 Feb 21
3
Initial statement of insider ownership
11 Feb 21
SC 13D/A
Innoviva / GLAXOSMITHKLINE ownership change
11 Feb 21
SC 13G/A
GLAXOSMITHKLINE / BlackRock ownership change
29 Jan 21
SC 13D/A
Spero Therapeutics / GLAXOSMITHKLINE ownership change
7 Dec 20
SC 13D/A
BICYCLE THERAPEUTICS / GLAXOSMITHKLINE ownership change
7 Dec 20
Transcripts
Reddit threads
What company next? ($100+ div/mo in portfolio achieved)
17 Apr 21
Morning Update for Thursday, 04/15/21
15 Apr 21
In-depth DD on Bio Stock Nearing Approval of Breakthrough Drug to Treat Depression: Axsome Therapeutics (AXSM)
12 Apr 21
In-depth DD on Bio Stock Nearing Approval of Breakthrough Drug to Treat Depression: Axsome Therapeutics (AXSM)
12 Apr 21
Uk dividends
12 Apr 21
Dividends stocks to get as a U.K. citizen?
11 Apr 21
$NVAX: Extremely Coiled and Right At The Very End of Pennant; Likely Major Breakout Above or Below Imminent Next Week. ///Relevant Tags: $SPX $SPY $QQQ $IBB $MRNA $PFE $GSK \\\
10 Apr 21
Psilocybin Mushrooms / Alternative Mental Health Industry
7 Apr 21
Who’s going long on Pfizer (PFE)?
7 Apr 21
Daily Advice Thread - All basic help or advice questions must be posted here.
6 Apr 21